Best Use Of Angiostatin May Be To Enhance Radiation Therapy

December 15, 1998

The team of scientists who discovered that angiostatin could dramatically boost the effects of radiation therapy has now shown that only brief exposure to angiostatin is required to get most of the drug's radiation-boosting anti-tumor effects. Without concomitant radiation therapy, additional exposure to low doses of this highly touted, costly and hard-to-obtain protein did not enhance treatment.

This latest report, by researchers from the University of Chicago Medical Center, Harvard Medical School and Northwestern University in the December 15 issue of Cancer Research, adds to the mounting enthusiasm about combining angiostatin with other forms of cancer therapy.

"The limited angiostatin supplies may be most effectively and efficiently used in combination with cytotoxic therapies such as ionizing radiation," note the authors. "These results suggest a new approach to the design of clinical trials with angiostatin and other anti-angiogenic agents."

The research team, led by Ralph Weichselbaum, M.D., professor and chairman of radiation oncology at the University of Chicago, tested the anti-tumor effects of angiostatin and radiation alone and in various combinations. They used large (500mm3), rapidly growing human tumors transplanted into mice.

As expected, the most effective therapy was the combination of simultaneous angiostatin and radiation therapy. What was not anticipated was how little angiostatin was required to make a big difference, or how limited the benefits would be from continuing to give low-dose angiostatin after completing a short course of radiation.

The study wasn't designed to assess the effects of angiostatin, used here in very small doses, but to determine the most effective and efficient ways to combine it with radiation therapy.

The research involved six groups of mice. One group received no treatment, one got angiostatin alone, and one group received radiation therapy.

Mice in the other three groups received different combinations of angiostatin and radiation. One group received angiostatin and radiation together for two days. One group received radiation for two days followed by angiostatin on days 2-14. One group both radiation and angiostatin for the first two days, followed by angiostatin on days 2 -14.

When their tumors were measured at day 9 and again at day 14, the mice that received both angiostatin and radiation together had the smallest tumors. Angiostatin dramatically improved the effects of radiation therapy if given at the same time, but at these low doses had little effect when given without same-day radiation therapy.
 
   

"This study extends our previous finding that angiostatin becomes much more effective when used to enhance the effects of radiation," said Weichselbaum, "and that radiation, already a standard of cancer therapy, could become more effective with a boost from short courses of concomitant low-dose angiostatin. This combination may be the most efficient, most beneficial use of this agent, which is in extremely short supply."

Angiogenesis inhibitors could make radiation much more effective at providing local control of cancer, Weichselbaum suggests. "Local control is a crucial part of treatment for many tumors, including prostate, brain, head & neck and other cancers," he added. "It could even expand the use of radiation therapy to some forms of metastatic disease without requiring high doses."

Additional authors of the paper include David Gorski, Helena Mauceri, Rabih Salloum, Michael Beckett, and Samuel Hellman from the University of Chicago; Vikas Sukhatme and Donald Kufe from Harvard; and Stephen Gately and Gerald Soff from Northwestern. Funding support came from the National Institutes of Health.
-end-


University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.